| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2016 | 134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC) | Jenkins S; CHIH-HSIN YANG ; Ramalingam S; Yu K; Patel S; Weston S; Lawrance R; Cantarini M; Jänne P; Mitsudomi T. | Journal of Thoracic Oncology | 16 | 16 | |
| 2016 | 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC | Oxnard G.R; Thress K.S; Alden R.S; Lawrance R; Paweletz C.P; Cantarini M; Barrett C; CHIH-HSIN YANG ; Jänne P. | Journal of Thoracic Oncology | 9 | 8 | |
| 2016 | 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial | Ahn M.-J; CHIH-HSIN YANG ; Yu H; Saka H; Ramalingam S; Goto K; Kim S.-W; Yang L; Walding A; Oxnard G.R. | Journal of Thoracic Oncology | 213 | 179 | |
| 2016 | 138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) | Schuler M; CHIH-HSIN YANG ; Sequist L.V; Yamamoto N; Zhou C; O'Byrne K; Hirsh V; Mok T; Shah R; Wu Y.-L. | Journal of Thoracic Oncology | 2 | 1 | |
| 2016 | 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations | Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG ; Mok T; Kim M; Paz-Ares L. | Journal of Thoracic Oncology | 2 | 2 | |
| 2016 | 151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs | BIN-CHI LIAO ; Bai Y.-Y.; CHIA-CHI LIN ; SHU-YUNG LIN ; YEE-FAN LEE ; CHAO-CHI HO ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 1 | 1 | |
| 2019 | 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer | Borghaei H; Langer C.J; Gadgeel S; Papadimitrakopoulou V.A; Patnaik A; Powell S.F; Gentzler R.D; Martins R.G; Stevenson J.P; Jalal S.I; Panwalkar A; CHIH-HSIN YANG ; Gubens M; Sequist L.V; Awad M.M; Fiore J; Saraf S; Keller S.M; Gandhi L. | Journal of Thoracic Oncology | 149 | 136 | |
| 2017 | Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib | CHAO-CHI HO ; WEI-YU LIAO ; Lin C.-A.; JIN-YUAN SHIH ; CHONG-JEN YU ; Chih-Hsin CHIH-HSIN YANG | Journal of Thoracic Oncology | 163 | 155 | |
| 2021 | Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC | BIN-CHI LIAO ; CHIH-HSIN YANG | Journal of Thoracic Oncology | 0 | 0 | |
| 2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; CHIA-CHI LIN ; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 74 | 64 | |
| 2018 | Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program | Peters, Solange; Curioni-Fontecedro, Alessandra; Nechushtan, Hovav; JIN-YUAN SHIH ; WEI-YU LIAO ; Gautschi, Oliver; Spataro, Vito; Unk, Mojca; CHIH-HSIN YANG ; Lorence, Robert M; Carrière, Philippe; Cseh, Agnieszka; Chang, Gee-Chen | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 56 | 51 | |
| 2008 | Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma | CHIA-CHI LIN ; YEONG-SHIAU PU ; CHIH-HUNG HSU ; Keng H.-Y.; ANN-LII CHENG ; CHIH-HSIN YANG | Urologic Oncology: Seminars and Original Investigations | 8 | 7 | |
| 2018 | Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI | Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok T.S.K; CHIH-HSIN YANG ; Hoyle C. | Clinical Drug Investigation | 14 | 14 | |
| 2012 | Advanced non-small cell lung cancer in patients aged 45 years or younger: Outcomes and prognostic factors | CHIA-LIN HSU ; KUAN-YU CHEN ; JIN-YUAN SHIH ; CHAO-CHI HO ; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | BMC Cancer | 71 | 67 | |
| 2015 | Advanced non-small cell lung cancer in the elderly: The impact of age and comorbidities on treatment modalities and patient prognosis | CHIA-LIN HSU ; JEN-HAU CHEN ; KUAN-YU CHEN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU ; PAN-CHYR YANG | Journal of Geriatric Oncology | 32 | 31 | |
| 2018 | Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials | Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG ; Paz-Ares L; Park K. | Clinical Lung Cancer | 47 | 39 | |
| 2016 | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial | Schuler M; CHIH-HSIN YANG ; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators | Annals of Oncology | 116 | 110 | |
| 2012 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial | CHIH-HSIN YANG ; JIN-YUAN SHIH ; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU ; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG ; Miller V.A. | The Lancet Oncology | 370 | 332 | |
| 2022 | Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report | CHIH-HSIN YANG ; Schuler, Martin; Popat, Sanjay; Miura, Satoru; Park, Keunchil; Passaro, Antonio; De Marinis, Filippo; Solca, Flavio; Märten, Angela; Kim, Edward S | Frontiers in oncology | 12 | 10 | |
| 2020 | Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases | CHIH-HSIN YANG ; Schuler M.; Popat S.; Miura S.; Heeke S.; Park K.; Märten A.; Kim E.S. | Journal of Thoracic Oncology | 134 | 131 | |
